

(51) International Patent Classification:
C07K 16/30 (2006.01)(21) International Application Number:
PCT/IB2015/051787(22) International Filing Date:
12 March 2015 (12.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/952,116	12 March 2014 (12.03.2014)	US
61/952,833	13 March 2014 (13.03.2014)	US
62/023,724	11 July 2014 (11.07.2014)	US
62/068,419	24 October 2014 (24.10.2014)	US

(71) Applicant: PROTHENA BIOSCIENCES LIMITED
[IE/IE]; 25-28 North Wall Quay, Dublin, 1 (IE).

(72) Inventors: LIU, Yue; 815 Peary Lane, Foster City, California 94404 (US). GARIDEL, Patrick; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). LANGER, Andreas; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE

(57) Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions and pharmaceutical formulations, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.

FIG.1



**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*